Chao Family Comprehensive Cancer Center

University of California, Irvine

Orange, CA

Sorting 5 by

Accepting patients

QUINTESSENTIAL-2

Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

Sonrotoclax (BGB-11417)

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Learn more
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

AZD0305

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Learn more
  • Antibody Drug Conjugate (ADC)
  • GPRC5D
  • Phase 1/2

Accepting patients

Iberdomide vs. Observation Post Ide-Cel CAR-T

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
Learn more
  • CELMoD
  • Maintenance
  • Randomization
  • Phase 2

Accepting patients

Teclistamab or Talquetamab

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 2
  • Has results
1 hidden based on your filters.Show All